Brief: Newamsterdam Pharma Reports Full Year 2022 Financial Results And Provides Corporate Update

NewAmsterdam Pharma

31/03/2023 13:10

March 31 (Reuters) - NewAmsterdam Pharma Company NV
 NAMS.O :
    * NEWAMSTERDAM PHARMA REPORTS FULL YEAR 2022 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
    * INITIATED PHASE 2 DOSE-FINDING STUDY EVALUATING
OBICETRAPIB IN
JAPANESE PATIENTS; EXPECT TO REPORT TOPLINE RESULTS IN 2H 2023
    * PIVOTAL PHASE 3 BROOKLN, BROADWAY AND PREVAIL TRIALS
ON-TRACK
    * EXTENDING EXPECTED CASH RUNWAY THROUGH 2026
    * AS OF DECEMBER 31, 2022, NEWAMSTERDAM HAD CASH OF 439
MILLION
EUROS
    * 2022 NET LOSS PER SHARE 0.96 EUROS

Source text for Eikon:  ID:nGNXtLjrd 
Further company coverage:  NAMS.O 

 ((Reutersbriefs@thomsonreuters.com;))